Introduction {#S0001}
============

Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare and highly aggressive lymphoma derived from mature NK- and T-cells, which accounts for less than 1% of non-Hodgkin lymphoma (NHL) in the Western world and up to 10% of NHL in Asia and South America.[@CIT0001] This disease is characterized by Epstein--Barr virus (EBV) infection and extranodal involvement, with 5-year overall survival (OS) rates of less than 50%.[@CIT0002]--[@CIT0004] ENKTL can be pathologically divided into two types, nasal and non-nasal ENKTL.[@CIT0004] About 80% of ENKTL cases occur in the nose, nasopharynx, oropharynx, and parts of the upper aerodigestive tract, and about 20% of them occur in non-nasal sites, including skin, testis, and salivary glands. Patients with nasal or paranasal involvement are defined as nasal type. Non-nasal cases presented more adverse clinical features and poor survival outcome.[@CIT0005] At present, no standard treatment has been established due to the rarity of this disease. Although L-asparaginase-based chemotherapy regimens and radiotherapy have brought improvement in the treatment strategy of ENKTL, the prognosis of these patients is still unsatisfactory.[@CIT0001],[@CIT0006],[@CIT0007]

The International Prognostic Index (IPI), including age, Ann Arbor stage, serum lactate dehydrogenase (LDH), performance status (PS), and number of extranodal sites, is a useful scoring model for predicting the prognosis of NHL.[@CIT0008] With the abandonment of anthracycline-based regimens and appearance of L-asparaginase-containing regimens, a new prognostic model, prognostic index for NK/T cell lymphoma (PINK), was established.[@CIT0009] The PINK score consists of four factors, including age, stage, distant lymph-node involvement, and non-nasal type. The prognostic significance of IPI and PINK in ENKTL patients have been verified in many studies.

In recent years, several studies have suggested that tumor microenvironment and host immune system played important roles in the pathogenesis and clinical outcome of human malignancies. Accumulating evidence suggested that the pre-treatment derived neutrophil to lymphocyte ratio (dNLR) was demonstrated to act as a significant prognostic factor in a variety of solid tumors, including non-small cell lung cancer, esophageal cancer, gastric cancer, breast cancer, and melanoma.[@CIT0010]--[@CIT0014] Nevertheless, the role of dNLR in hematological malignancies was rarely reported.[@CIT0015]

Lymphocytes play a crucial role in the tumor-related immune response. Elevated levels of absolute lymphocyte count (ALC) were demonstrated to be associated with favorable prognosis in several types of solid tumors, such as gastric cancer, bladder cancer and ovarian cancer.[@CIT0016]--[@CIT0019] As a surrogate of host immunity impairment, ALC was reported to be a prognostic indicator in hematological malignancies, including multiple myeloma (MM), primary central nervous system lymphoma (PCNSL), and anaplastic large cell lymphoma (ALCL).[@CIT0020]--[@CIT0022] In addition, ALC was also incorporated into the International Prognostic Score (IPS) of Hodgkin lymphoma (HL).[@CIT0023],[@CIT0024]

However, the significance of dNLR and ALC in the tumor progression and treatment response in patients with ENKTL is still unclear. In the present study, we evaluated the prognostic value of dNLR and ALC in newly diagnosed ENKTL patients.

Patients and methods {#S0002}
====================

Study population {#S0002-S2001}
----------------

We conducted a retrospective study of a cohort of 33 patients with newly diagnosed ENKTL from February 2010 to June 2018 at Shandong Provincial Hospital affiliated to Shandong University. All diagnoses were based on the criteria of the WHO 2016 Classifications of the Tumors and Hematopoietic and Lymphoid Tissues.[@CIT0025] Inclusion criteria were histopathologically confirmed of ENKTL, and pre-treatment values of white blood cell (WBC) count, ALC, absolute neutrophil count (ANC), and other clinical data. This study was approved by the Medical Ethical Committee of Shandong Provincial Hospital affiliated to Shandong University. All data of the recruited patients were obtained with written informed consent in accordance with the Declaration of Helsinki.

Data gathering {#S0002-S2002}
--------------

The pretreatment clinical-pathological data, such as age, gender, Ann-Arbor stage, B symptoms, Eastern Cooperative Oncology Group (ECOG) performance status (PS) score, serum LDH levels, bone marrow involvement, β2-microglobulin (β2-MG), blood EBV-DNA level, WBC, ANC, ALC, PINK score, and IPI score were collected.

Calculation of derived neutrophil/lymphocyte ratio (dNLR) {#S0002-S2003}
---------------------------------------------------------

The WBC and ANC were obtained at patient enrollment. The dNLR was calculated by a formula as \[dNLR=ANC/(WBC-ANC)\], which was previously verified to have predictive power in cancer patients.[@CIT0026]

Treatment {#S0002-S2004}
---------

The therapeutic strategies of the included patients consist of chemotherapy alone, radiotherapy alone and combined chemoradiotherapy. The chemotherapy regimens included P-CHOP (pegaspargase, cyclophosphamide, doxorubicin, vincristine, and prednisone), P-CHOPE (pegaspargase, CHOP, and etoposide), L-EPOCH (L-asparaginase, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), SMILE (dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide), GELOX (gemcitabine, pegaspargase, and oxaliplatin) and P-GemOX (pegaspargase, gemcitabine, and oxaliplatin). Radiotherapy used was no more than 56 Gy (range, 42 to 56 Gy). Response to the treatment includes complete remission (CR) or partial remission (PR), no response to treatment includes stable disease (SD) or progressive disease (PD).

Statistic analysis {#S0002-S2005}
------------------

OS was defined as interval from the date of diagnosis to the date of last follow-up or death. Progression-free survival (PFS) was calculated as interval from the date of diagnosis to date of disease progression. The differences of the quantitative variables were compared by Mann--Whitney U test or Student\'s *t*-test. Fisher exact test was used for categorical variables. The optimal cutoff points of dNLR and ALC were determined by receiver operating characteristics curve (ROC) and area under curve (AUC). Survival analyses were performed using the Kaplan--Meier method and the log-rank test was used to calculate for significant differences. Univariate and multivariate analyses were performed using the Cox proportional-hazards regression model. Statistical analyses were performed by SPSS software for Windows ver. 20.0 (SPSS Inc, Chicago, IL, USA). *P*-value of \<0.05 was considered statistically significant.

Results {#S0003}
=======

Clinical characteristics of patients {#S0003-S2001}
------------------------------------

A total of 33 patients with pathological diagnosis of ENKTL were included in this study, including 26 (78.8%) male patients and 7 (21.1%) female patients. The median age at diagnosis was 50 years (range, 13--75 years), and 6 (18.2%) of them were more than 60 years old. About 60.6% (n=20) of them presented B symptoms. The number of patients with stage I/II and III/IV were 13 (39.4%) and 20 (60.6%), respectively. The majority of them (78.8%, n=26) had good performance status (ECOG PS score 0/1). Nineteen (58%) of the included patients revealed elevated β2-MG level and 16 (48.5%) patients presented high IPI score (IPI ≥2). patients were treated with chemotherapy alone (51.5%, n=17), radiotherapy alone (33.3%, n=11) or combined chemoradiotherapy (15.2%, n=5). One patient received salvage allogeneic hematopoietic stem cell transplantation (HSCT). Among them, 15 (45.5%) exhibited a response to the first-line therapy. The baseline clinical characteristics are described in [Table 1](#T0001){ref-type="table"}.Table 1Correlation between dNLR and clinical characteristics of ENKTL patientsTotal (%)dNLRALCMean ± SD*P*-valueMean ± SD*P*-value33**Gender**0.1290.602 Male26 (78.8%)2.658±1.8041.264±0.616 Female7 (21.2%)1.570±0.5841.109±0.690**Age (year)**0.5880.664 \<6027 (81.8%)2.503±1.7871.208±0.602 ≥606 (18.2%)2.084±1.0951.333±0.774**Ann Arbor Stage0.047**0.188 I/II13 (39.4%)1.801±0.8321.410±0.539 III/IV20 (60.6%)2.834±1.9621.115±0.661**B symptoms**0.1940.941 Absence13 (39.4%)2.018±0.8071.221±0.523 Presence20 (60.6%)2.693±2.0331.238±0.693**ECOG PS score0.0500.002** 0 or 126 (78.8%)1.942±0.9251.381±0.550 ≥27 (21.2%)4.612±2.5560.555±0.501**Serum LDH0.0260.01** Normal18 (54.5%)2.235±1.2721.478±0.476 Increased\<3×NL9 (27.3%)1.763±1.2431.130±0.461 Increased≥3×NL6 (18.3%)3.999±2.4740.642±0.854**Extranodal site**0.4580.231 0 or 121 (63.6%)2.233±1.2851.331±0.584 ≥212 (36.4%)2.768±2.2301.057±0.679**Distant lympho node0.0130.026** Not involved13 (39.4%)1.651±0.7451.525±0.460 Involved20 (60.6%)2.932±1.9191.040±0.652**BM involvement**0.7150.085 Absence31 (93.9%)2.348±1.5511.278±0.612 Presence2 (6.1%)3.648±3.8240.495±0.318**β2-microglobulin0.0350.029** \<2.8 mg/L19 (58%)1.825±0.7751.451±0.429 ≥2.8 mg/L14 (42%)3.245±2.1980.933±0.734**Blood EBV DNA**0.126**0.011** \<5,000 copies/mL19 (57.6%)1.991±0.9421.462±0.527 ≥5,000 copies/mL14 (42.4%)3.019±2.2430.917±0.625**Treatment**0.8790.504 RT alone11 (33.3%)2.418±1.8771.394±0.522 CT alone17 (51.5%)2.533±1.7861.109±0.678 Combined RT and CT5 (15.2%)2.087±0.8491.286±0.678**Response**0.1230.349 No response (SD, PD)18 (54.5%)2.819±2.0751.141±0.752 Response (CR, PR)15 (45.5%)1.957±0.8711.339±0.425**PINK score**0.2360.125 0 or 117 (51.5%)2.088±1.3381.394±0.524 ≥216 (48.5%)2.788±1.9531.058±0.690**IPI Score0.0440.024** 0 or 117 (51.5%)1.837±0.7871.465±0.571 ≥216 (48.5%)3.055±2.1260.923±0.597[^2]

The association between clinicopathologic variables and dNLR, ALC {#S0003-S2002}
-----------------------------------------------------------------

We next assessed the association between clinicopathologic variables and dNLR as well as ALC in the included ENKTL patients. Among them, the median value of dNLR was 1.79 (range, 0.427--7.6). 39.4% (n=13) patients were diagnosed at stage I/II with the mean dNLR of 1.801±0.832, versus 60.6% (n=20) at stage III/IV with the mean dNLR of 2.834±1.962 (*P*=0.047). In addition, the dNLR levels were significantly higher in ENKTL patients with elevated serum LDH (*P*=0.026), distant lymph-node involvement (*P*=0.013), high β2-MG (*P*=0.035), and high IPI score (*P*=0.044, [Table 1](#T0001){ref-type="table"}). Low ALC levels were significantly associated with high ECOG PS score (*P*=0.002), elevated serum LDH (*P*=0.01), distant lymph-node involvement (*P*=0.026), elevated β2-MG (*P*=0.029), high IPI score (*P*=0.024), and increased blood EBV DNA levels (*P*=0.011, [Table 1](#T0001){ref-type="table"}).

Correlation between dNLR, ALC, and clinical outcomes {#S0003-S2003}
----------------------------------------------------

The ROC analysis was performed to determine the specificity and sensitivity of dNLR and ALC, respectively. The most discriminative cutoff value of dNLR was 3.6, with an AUC value of 0.714 (95% confidence interval \[CI\], 0.524--0.904, *P*=0.043, [Figure 1A](#F0001){ref-type="fig"}). The most discriminative cutoff value of ALC was 0.8×10^9^/L, with an AUC value of 0.738 (95% CI, 0.523--0.953, *P*=0.025, [Figure 1B](#F0001){ref-type="fig"}). Based on the above results, we selected dNLR of 3.6 and ALC of 0.8×10^9^/L as the optimal cutoff points for survival analysis in the entire cohort.Figure 1ROC curves for dNLR **(A)** and ALC **(B)** at diagnosis.**Abbreviations:** ALC, absolute lymphocyte count; AUC, area under the curve; dNLR, derived neutrophil to lymphocyte ratio; ROC, receiver operating characteristic.

Clinical indicators according to the dNLR and ALC at diagnosis are shown in [Table 2](#T0002){ref-type="table"}. Patients with dNLR of ≥3.6 presented adverse pre-treatment factors, including higher ECOG PS score (*P*=0.004), elevated serum LDH level (*P*\<0.001), increased β2-MG (*P*=0.008), and high IPI score (*P*=0.018, [Table 2](#T0002){ref-type="table"}). In addition, patients with dNLR ≥3.6 showed worse response to treatment compared to those with dNLR \<3.6 (*P*=0.049, [Table 2](#T0002){ref-type="table"}). Patients with ALC of \<0.8×10^9^/L presented high ECOG PS score (*P*=0.009), elevated serum LDH level (*P*=0.001), increased β2-MG level (*P*=0.02), elevated blood EBV DNA level (*P*=0.019), and distant lymph-node involvement (*P*=0.047, [Table 2](#T0002){ref-type="table"}). ENKTL patients with ALC \<0.8×10^9^/L revealed more inferior treatment response compared to those with ALC ≥0.8×10^9^/L (*P*=0.021, [Table 2](#T0002){ref-type="table"}).Table 2Association between clinical variables and dNLR, ALCVariablesTotal (n=33)dNLR≥3.6\
(n=5)dNLR\<3.6\
(n=28)*P*-valueALC≥0.8×10^9^/L\
(n=24)ALC\<0.8×10^9^/L\
n=9*P*-value**Gender**0.5590.358 Male265 (100.0%)21 (75.0%)20 (83.3%)6 (66.7%) Female70 (0.0%)7 (25.0%)4 (16.7%)3 (33.3%)**Age (year)**11 \<60274 (80.0%)23 (82.1%)20 (83.3%)7 (77.8%) ≥6061 (20.0%)5 (17.9%)4 (16.7%)2 (22.2%)**Ann Arbor Stage**0.1310.263 I/II130 (0.0%)13 (46.4%)11 (45.8%)2 (22.2%) III/IV205 (100.0%)15 (53.6%)13 (54.2%)7 (77.8%)**B symptoms**0.1311 Absence130 (0.0%)13 (46.4%)10 (41.7%)3 (33.3%) Presence205 (100.0%)15 (53.6%)14 (58.3%)6 (66.7%)**ECOG PS score0.0040.009** 0 or 1261 (20.0%)25 (89.3%)22 (91.7%)4 (44.4%) ≥274 (80.0%)3 (10.7%)2 (8.3%)5 (55.6%)**Serum LDH\<0.0010.001** Normal181 (20.0%)17 (60.7%)17 (70.8%)1 (11.1%) Increased\<3×ULN90 (0.0%)9 (32.1%)6 (25.0%)3 (33.3%) Increased≥3×ULN64 (80.0%)2 (7.2%)1 (4.2%)5 (55.6%)**Distant lympho node**0.131**0.047** Not involved130 (0.0%)13 (46.4%)13 (54.2%)1 (11.1%) Involved205 (100.0%)15 (53.6%)11 (45.8%)8 (88.9%)**BM involvement**0.2840.068 Absence314 (80.0%)27 (96.4%)24 (100.0%)7 (77.8%) Presence21 (20.0%)1 (3.6%)0 (0.0%)2 (22.2%)**β2-microglobulin0.0080.02** \<2.8 mg/L190 (0.0%)19 (67.9%)18 (75.0%)1 (11.1%) ≥2.8 mg/L145 (100.0%)9 (32.1%)6 (25.0%)8 (88.9%)**Blood EBV DNA**0.628**0.019** \<5,000 copies/mL192 (40.0%)17 (60.7%)17 (70.8%)2 (22.2%) ≥5,000 copies/mL143 (60.0%)11 (39.3%)7 (29.2%)7 (77.8%)**Treatment**0.3440.163 RT alone111 (20.0%)10 (35.7%)10 (41.7%)1 (11.1%) CT alone174 (80.0%)13 (46.4%)10 (41.7%)7 (77.8%) Combined RT and CT50 (0.00%)5 (17.9%)4 (16.7)1 (11.1%)**Response0.04**9**0.021** No response (SD, PD)185 (100.0%)13 (46.4%)10 (41.7%)8 (88.9%) Response (CR, PR)150 (0.0%)15 (53.6%)14 (58.3%)1 (11.1%)**PINK**0.1750.269 0 or 1171 (20.0%)16 (57.1%)14 (58.3%)3 (33.3%) ≥2164 (80.0%)12 (42.9%)10 (41.7%)6 (66.7%)**IPI Score0.018**0.057 0 or 1170 (0.0%)17 (60.7%)15 (62.5%)2 (22.2%) ≥2165 (100.0%)11 (39.3%)9 (37.5%)7 (77.8%)[^3]

Survival analysis of dNLR and ALC {#S0003-S2004}
---------------------------------

Survival analysis revealed that ENKTL patients with high dNLR (≥3.6) revealed significantly shorter OS (*P*=0.001) and PFS (*P*=0.008) than those with low dNLR (\<3.6, [Figures 2A](#F0002){ref-type="fig"} and [3A](#F0003){ref-type="fig"}). Patients with an ALC of \<0.8×10^9^/L had worse OS (*P*\<0.001) and PFS (*P*\<0.001) than those with an ALC of ≥0.8×10^9^/L ([Figures 2B](#F0002){ref-type="fig"} and [3B](#F0003){ref-type="fig"}).Figure 2Kaplan--Meier curve of overall survival according to dNLR **(A)** and ALC **(B)** at diagnosis in patients with ENKTL.**Abbreviations:** ALC, absolute lymphocyte count; AUC, area under the curve; dNLR, derived neutrophil to lymphocyte ratio; ENKTL, extranodal natural killer/T-cell lymphoma.Figure 3Kaplan--Meier curve of progression-free survival according to dNLR **(A)** and ALC **(B)** at diagnosis in patients with ENKTL.**Abbreviations:** ALC, absolute lymphocyte count; AUC, area under the curve; dNLR, derived neutrophil to lymphocyte ratio; ENKTL, extranodal natural killer/T-cell lymphoma.

The prognostic value of dNLR was further evaluated in accordance with stage. In advanced stage (stage III/IV) ENKTL patients, dNLR ≥3.6 signified shorter survival for both OS (*P*=0.048) and PFS (*P*=0.026, [Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}), while in early stage (stage I/II) patients, dNLR ≥3.6 presented no significant difference in the OS and PFS of patients. We further analyzed the effect of ALC on the survival of ENKTL patients according to stage. Advanced stage (stage III/IV) patients with ALC \<0.8×10^9^/L exhibited significantly shorter OS (*P*=0.002) and PFS (*P*=0.001, [Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}). Nevertheless, no significant difference of survival time (OS, PFS) was found between low ALC group (ALC \<0.8×10^9^/L) and high ALC group (ALC ≥0.8×10^9^/L) in ENKTL patients with early stage (stage I/II).Figure 4Kaplan--Meier curve of overall survival and progression-free survival according to dNLR **(A** and **B)** and ALC **(C** and **D)** at diagnosis in ENKTL patients with stage III/IV disease.**Abbreviations:** ALC, absolute lymphocyte count; AUC, area under the curve; dNLR, derived neutrophil to lymphocyte ratio; ENKTL, extranodal natural killer/T-cell lymphoma.

Analysis of prognostic indicators {#S0003-S2005}
---------------------------------

We next explored the correlation between clinical characteristics and survival of ENKTL patients using univariate and multivariate analyses. Univariate Cox proportional analysis revealed that high ECOG PS score (≥2; HR, 4.865; 95%CI, 1.477--16.030; *P*=0.009), elevated β2-MG (≥2.8 mg/L; HR, 4.795; 95%CI, 1.223--18.809; *P*=0.025), high IPI score (≥2; HR, 6.332; 95%CI, 1.379--29.074; *P*=0.018), low ALC (\<0.8×10^9^/L; HR, 11.251; 95%CI, 2.946--42.968; *P*=0.0004) and elevated dNLR (\>3.6; HR, 5.938; 95%CI, 1.790--19.704; *P*=0.004) were correlated with worse OS of ENKTL patients ([Table 3](#T0003){ref-type="table"}). Next, we put the stage, ECOG PS score, serum LDH, distant lymph-node involvement, β2-MG, IPI score, ALC, and dNLR into the multivariate Cox model. In multivariate analysis, we identified that ALC \<0.8×10^9^/L (HR, 36.023; 95%CI, 2.438--532.243; *P*=0.009) at diagnosis was an independent prognostic factor for the OS of ENKTL patients ([Table 3](#T0003){ref-type="table"}). However, the dNLR value at diagnosis was not of significance in multivariate analysis.Table 3Univariate and multivariate Cox regression analysis of overall survival in patients with ENKTLPrognostic factorsOverall survivalUnivariate analysisMultivariate analysisHR (95% CI)*P*-valueHR (95% CI)*P*-valueMale sex0.342 (0.095--1.227)0.1n.d.n.d.Age≥60 years0.463 (0.059--3.659)0.465n.d.n.d.Stage III/IV7.378 (0.949--57.353)0.0569.202 (0.567--149.365)0.119B symptoms1.285 (0.381--4.328)0.686n.d.n.d.ECOG PS score ≥24.865 (1.477--16.030)**0.009**2.520 (0.183--34.801)0.490Serum LDH \> normal3.373 (0.979--11.614)0.0541.674 (0.329--8.510)0.535Distant lympho node involved3.237 (0.705--14.857)0.131n.d.n.d.BM involvement3.267 (0.691--15.454)0.135n.d.n.d.β2-MG ≥2.8mg/L4.795 (1.223--18.809)**0.025**0.556 (0.030--10.246)0.693Blood EBV DNA ≥5,000 copies/mL2.714 (0.814--9.054)0.104n.d.n.d.No response to treatment61.243 (0.573--6,543.069)0.084n.d.n.d.PINK score ≥22.356 (0.704--7.891)0.165n.d.n.d.IPI Score ≥26.332 (1.379--29.074)**0.018**1.358 (0.142--12.955)0.790ALC\<0.8×10^9^/L11.251 (2.946--42.968)**0.0004**36.023 (2.438--532.243)**0.009**dNLR ≥3.65.938 (1.790--19.704)**0.004**0.103 (0.05--2.098)0.140[^4]

In terms of PFS, univariable analysis identified several potential prognostic factors affecting PFS, including elevated serum LDH level (HR, 3.733; 95%CI, 1.111--12.541; *P*=0.033), ALC \<0.8×10^9^/L (HR, 7.392; 95%CI, 2.213--24.693; *P*=0.001), and dNLR ≥3.6 (HR, 4.199; 95%CI, 1.326--13.297; *P*=0.015). In multivariate Cox analysis, it was also found that ALC \<0.8×10^9^/L at diagnosis cloud independently predicts worse PFS in patients with ENKTL (HR, 7.698; 95%CI, 1.573--37.679; *P*=0.012; [Table 4](#T0004){ref-type="table"}).Table 4Univariate and multivariate Cox regression analysis of progression-free survival in patients with ENKTLPrognostic FactorsProgression-free survivalUnivariate analysisMultivariate analysisHR (95% CI)*P*-valueHR (95% CI)*P*-valueMale sex0.371 (0.107--1.281)0.117n.d.n.d.Age≥60 years1.664 (0.439--6.312)0.454n.d.n.d.Stage III/IV1.807 (0.486--6.727)0.378n.d.n.d.B symptoms1.351 (0.402--4.539)0.626n.d.n.d.ECOG PS score ≥22.568 (0.809--8.147)0.109n.d.n.d.Serum LDH \> normal3.733 (1.111--12.541)**0.033**2.063 (0.534--7.968)0.294Distant lympho node Involved4.412 (0.963--20.206)0.056n.d.n.d.BM involvement2.799 (0.598--13.098)0.191n.d.n.d.β2-MG ≥2.8 mg/L3.350 (0.972--11.541)0.055n.d.n.d.Blood EBV DNA≥5,000 copies/mL3.588 (0.968--13.295)0.056n.d.n.d.No response to treatment68.634 (0.655--7,191.306)0.075n.d.n.d.PINK score ≥21.405 (0.442--4.471)0.564n.d.n.d.IPI Score ≥23.426 (0.923--12.717)0.066n.d.n.d.ALC \<0.8×10^9^/L7.392 (2.213--24.693)**0.001**7.698 (1.573--37.679)**0.012**dNLR ≥3.64.199 (1.326--13.297)**0.015**0.615 (0.131--2.894)0.539[^5]

Discussion {#S0004}
==========

The host immune system, inflammation, and tumor microenvironment have been recognized to contribute to the development and progression of human malignancies.[@CIT0027] Lymphocyte count is a marker of host immune and lymphopenia is considered as a suggestion of immunocompetence.[@CIT0028] As a surrogate marker of host immunity, ALC has a potent effect in anti-tumor immunity, and is related to the treatment response of several hematological neoplasms. It was reported that ALC higher than 350 cells/μL measured on the 33rd day of induction therapy was associated with better OS and event-free survival (EFS) in acute lymphoblastic leukemia (ALL).[@CIT0029] Moreover, the day 100 ALC/AMC ratio could independently predict the outcomes in children, adolescents, and young adults with refractory/relapsed (R/R) HL who underwent autologous stem cell transplantation (ASCT).[@CIT0024] Kim et al illustrated that an early recovery of ALC (\>0.4×10^9^/L at 15 days) after frontline ASCT can be regarded as a good prognostic marker in patients diffuse large B-cell lymphoma (DLBCL).[@CIT0030] In this study, we identified that ENKTL patients with low ALC (\<0.8×10^9^/L) revealed inferior response to treatment and shorter survival time compared to those with higher ALC (≥0.8×10^9^/L).

Previous studies mainly focused on the involvement and prognostic value of non-immune factors in ENKTL, such as EBV DNA.[@CIT0031] More recently, several studies investigated the prognostic value of ALC in T-cell NHL. Peripheral T-cell lymphomas -- not otherwise specified (PTCL-NOS) patients with lower ALC/AMC ratios showed shorter survival than patients with high ALC/AMC ratios.[@CIT0032] Our study retrospectively evaluated the prognostic significance of ALC in 33 newly diagnosed ENKTL patients. Through univariate analysis as well as multivariate analysis, we identified that low ALC is a poor independent prognostic factor for clinical outcome. Consistent with previous studies, the decreasing ALC, a circulating immune cell which was considered as an indicator of immune suppression, was considered as an unfavorable prognostic marker for ENKTL.[@CIT0033]

The peripheral pro-inflammatory parameters, such as neutrophils, albumin, LDH, and C-reactive protein (CRP), have been reported to be associated with poor outcomes in patients with tumors.[@CIT0034] As an indicator of systemic inflammation, the dNLR was validated to act as an independent prognostic factor in cancer.[@CIT0026] The dNLR has been proposed as an alternative to NLR because of its convenience in cases with only WBC and ANC recorded.[@CIT0026] It was demonstrated that high dNLR was associated with poor survival outcome in a variety of tumor types, including melanoma, pancreatic cancer, bladder cancer, and renal cancer.[@CIT0035]--[@CIT0039] As it is inexpensive and easy to calculate, dNLR could be routinely detected in the clinical practice. Recently, several studies focused on the prognostic value of dNLR in patients receiving immuno-modulating therapy. In melanoma, dNLR of ≥3 exhibited an independent negative effect on the OS of ipilimumab-treated melanoma patients (n=720).[@CIT0035] In addition, the pretreatment dNLR level in NSCLC was correlated with poor clinical outcome for checkpoint inhibitor therapy.[@CIT0010] In hematological malignancies, Troppan et al reported that dNLR ≥1.8 was a significant factor for 5-year disease-free survival (DFS) in DLBCL patients treated with standard rituximab and CHOP (R-CHOP) regimen.[@CIT0015] Elevated NLR (≥2.95) was related to inferior OS in MM patients receiving induction therapy with bortezomib-based regimens.[@CIT0040] Our present study demonstrated that ENKTL patients who received first-line therapy with high dNLR (≥3.6) presented lower response (CR or PR) rate when compared to patients with lower dNLR.

The prognostic effects of dNLR in hematological malignancies have been recently reported. Elevated dNLR level was an independent poor prognostic factor for transplantation-ineligible MM patients with MM.[@CIT0041] Independent significant association between dNLR and poor OS as well as DFS was identified in DLBCL.[@CIT0015] However, the prognostic significance of dNLR in ENKTL has not been reported. By multivariate analysis, we found that dNLR levels were associated with poor OS and PFS in ENKTL patients. Nevertheless, no significant effect was found in dNLR in multivariable analysis, which might be related to the small number of included cases and relatively short time of follow-up.

However, there are still several limitations to this study. This is a retrospective study in a single center. Prospective randomized studies are warranted to verify the significance of these indexes for patients after first-line therapy. Moreover, due to the rarity of ENKTL, the number of patients included in this study is limited. Further investigations with larger population cohorts and longer median follow-up are needed to validate the prognostic value of dNLR, ALC in ENKTL patients.

Conclusion {#S0005}
==========

In conclusion, our finding demonstrated that elevated dNLR (≥3.6) was associated with short survival time and inferior therapeutic response in ENKTL, which may act as a potential prognostic factor in patients with ENKTL. Low ALC (\<0.8×10^9^/L) at diagnosis of ENKTL represented an independent poor prognostic factor for clinical outcome. The dNLR and ALC may serve as a novel, convenient, inexpensive and independent prognostic factors for patients with untreated ENKTL.
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